The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Stem Cell Therapy For Multiple Sclerosis Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The stem cell therapy for multiple sclerosis market size has witnessed swift growth in recent years. It is forecast to grow from $1.82 billion in 2025 to $2.05 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.4%. This growth in the historic period can be attributed to advancements in multiple sclerosis treatment research, increasing diagnosis rates of autoimmune disorders, the expansion of stem cell clinical trials, improved patient selection protocols, and the growing availability of specialized neurology centers.
The market for stem cell therapy targeting multiple sclerosis is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $3.24 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.2%. Several factors are expected to fuel this growth during the forecast period, including the accumulation of more extensive long-term efficacy data for stem cell therapies, a growing need for disease-modifying interventions, the broadening scope of personalized neurology care, increased funding directed towards neuro-regenerative research, and stronger partnerships between healthcare facilities and research organizations. Key trends characterizing this period are the greater acceptance of autologous hematopoietic stem cell transplants, an intensified emphasis on therapies aimed at resetting the immune system, the expanding application of mesenchymal stem cells, the heightened utilization of targeted delivery approaches, and advancements in clinical monitoring and outcome assessment.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=30409&type=smp
Which Growth Drivers Are Contributing To The Progress Of The Stem Cell Therapy For Multiple Sclerosis Market?
The growing occurrence of multiple sclerosis (MS) is anticipated to significantly contribute to the future expansion of the stem cell therapy for multiple sclerosis market. MS is a chronic autoimmune condition that targets the central nervous system by harming the protective myelin sheath around nerve fibers, which disrupts communication between the brain and body and manifests as symptoms such as fatigue, muscle weakness, and vision issues. The rising incidence of MS is predominantly linked to improvements in diagnostic capabilities, as advancements in medical imaging and increased public awareness allow for more accurate and earlier detection of cases, resulting in higher reported figures. Stem cell therapy for multiple sclerosis assists in mending compromised myelin, moderating abnormal immune reactions, and fostering nerve cell regeneration, thereby helping to lessen symptoms and potentially slow down the disease’s advancement. For instance, in May 2024, the MS Trust, a UK-based organization, reported that approximately 2.9 million people globally are affected by multiple sclerosis, including more than 150,000 individuals living with the condition in the UK. Therefore, the increasing prevalence of multiple sclerosis is poised to drive the growth of the stem cell therapy for multiple sclerosis market.
What Major Segment Divisions Exist Within The Stem Cell Therapy For Multiple Sclerosis Market?
The stem cell therapy for multiple sclerosis market covered in this report is segmented –
1) By Type Of Stem Cell: Embryonic Stem Cells, Adult Stem Cells, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Hematopoietic Stem Cells
2) By Treatment Approach: Autologous Stem Cell Therapy, Allogeneic Stem Cell Therapy
3) By Delivery Method: Intravenous Injection, Intrathecal Injection, Direct Intraspinal Administration
4) By Application: Relapsing-Remitting Multiple Sclerosis (RRMS), Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Progressive Relapsing Multiple Sclerosis (PRMS)
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Embryonic Stem Cells: Inner Cell Mass Cells, Blastocyst Derived Cells, Totipotent Stem Cells
2) By Adult Stem Cells: Bone Marrow Stem Cells, Neural Stem Cells, Tissue Specific Stem Cells
3) By Induced Pluripotent Stem Cells: Reprogrammed Somatic Cells, Patient Derived Cells
4) By Mesenchymal Stem Cells: Adipose Derived Stem Cells, Umbilical Cord Derived Stem Cells, Bone Marrow Derived Stem Cells
5) By Hematopoietic Stem Cells: Peripheral Blood Stem Cells, Bone Marrow Stem Cells, Umbilical Cord Blood Stem Cells
What Trends Are Advancing Progress In The Stem Cell Therapy For Multiple Sclerosis Market?
Companies operating within the stem cell therapy for multiple sclerosis market are concentrating on developing innovative products, such as adipose-derived mesenchymal stem cells, to improve the efficacy, safety, and regenerative capacity of treatments for patients with relapsing-remitting and progressive forms of multiple sclerosis. Adipose-derived mesenchymal stem cells (ADMSCs) are multipotent stem cells derived from adipose (fat) tissue, capable of differentiating into multiple cell types and exhibiting regenerative and immunomodulatory properties that are beneficial in treating autoimmune and neurodegenerative diseases like multiple sclerosis. For instance, in August 2025, Hope Biosciences, LLC, a US-based biopharmaceutical company, introduced its HB-adMSCs therapy. This therapy utilizes adipose-derived mesenchymal stem cells administered through high-dose infusions and repeat dosing over a 32-week period. The treatment combines immunomodulatory and neuroregenerative mechanisms, offering the potential to decelerate disease progression and repair myelin damage, thereby distinguishing it from conventional immunosuppressive treatments.
Which Companies Are Leading Innovation In The Stem Cell Therapy For Multiple Sclerosis Market?
Major companies operating in the stem cell therapy for multiple sclerosis market are Sana Biotechnology Inc., Century Therapeutics Inc., Reelabs Private Limited, PlacidWay LLC, MedAccess Guarantee Ltd, Celltex Therapeutics Corporation, CELLTEX THERAPEUTICS CORP, BrainStorm Cell Therapeutics Ltd., Athersys Inc., Advancells Dermaceuticals Private Limited, ImStem Biotechnology Inc., NeuroGenesis Bio Inc., Stem Cell Medicine Ltd., Biotherapy International, R3 Stem Cell, Hope Biosciences LLC, FibroBiologics Inc., Global Institute of Stem Cell Therapy and Research Inc., ProgenCell, Stemwell
Read the full stem cell therapy for multiple sclerosis market report here:
What Are The Leading Geographic Regions In The Stem Cell Therapy For Multiple Sclerosis Market?
North America was the largest region in the stem cell therapy for multiple sclerosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stem cell therapy for multiple sclerosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Stem Cell Therapy For Multiple Sclerosis Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=30409&type=smp
Browse Through More Reports Similar to the Global Stem Cell Therapy For Multiple Sclerosis Market 2026, By The Business Research Company
Human Embryonic Stem Cells Global Market Report
https://www.thebusinessresearchcompany.com/report/human-embryonic-stem-cells-global-market-report
Stem Cell Manufacturing Global Market Report
https://www.thebusinessresearchcompany.com/report/stem-cell-manufacturing-global-market-report
Autologous Stem Cell And Non Stem Cell Based Therapies Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model